BioCentury
ARTICLE | Clinical News

Yungjin begins Phase I of NAD+ modulator KL1333

July 5, 2017 7:47 PM UTC

Yungjin Pharmaceutical Co. Ltd. (KSE:003520) began a double-blind, placebo-controlled, dose-escalation, Korean Phase I trial to evaluate safety and pharmacokinetics of single doses of oral KL1333 in 60 healthy volunteers.

The product is a nicotinamide adenine dinucleotide (NAD+) modulator. It is in development for mitochondrial disorders including mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS); Kearns-Sayre syndrome (KSS); progressive external ophthalmoplegia; Pearson syndrome; myoclonic epilepsy with ragged-red fibers (MERFF) and Alpers syndrome...